References
- van den Berg F M, Tiggers A J, Schipper M EI, et al. Expression of the nuclear oncogene p53 in colonic tumours. J Pathol 1989; 157: 193–9
- Cattoretti G, Rilke F, Andreola S, et al. p53 expression in breast cancer. Int J Cancer 1988; 41: 178–83
- Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675–9
- Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63: 739–46
- Lane D P, Crawford LV. T antigen is bound to a host protein in SV-40 transformed cells. Nature 1979; 278: 261–3
- Jenkins J R, Rudge K, Currie GA. Cellular immortalization of a cDNA clone encoding the transformation–associated phosphoprotein p53. Nature 1984; 312: 651–4
- De Leo A B, Jay G, Appella E, et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979; 76(5)2420–4
- Eliyahu D, Raz A, Gruss P, et al. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984; 312: 646–9
- Mowat M, Cheng A, Kimura N, et al. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend Virus. Nature 1985; 314: 633–6
- Nigro J M, Baker S J, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705–8
- Baker S J, Fearon E R, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217–21
- Mashal R, Shtalrid M, Talpaz M, et al. Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukaemia. Blood 1990; 75: 180–9
- Finlay C, Hinds P W, Tan TH, et al. Activating mutations for transformation by p53 produce a gene product that forms an hsc-70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8: 531–9
- Eliyahu D, Michalovitz D, Eliyahu S, et al. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989; 86: 8763–7
- Herskowitz I. Functional inactivation of genes by dominant negative mutations. Nature 1987; 329: 219–22
- Purdie C A, O'Grady J, Piris J, et al. p53 expression in colorectal tumors. Am J Pathol 1991; 138: 807–13
- Ostrowski J L, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immuno-histochemical study. J Pathol 1991; 64: 75–81
- Rodrigues N R, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555–9
- Barton C M, Staddon S L, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64: 1076–82
- Ogden G, Kiddie R, Lunny D, et al. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992; 166: 389–94
- Zur Hausen H. Viruses in human cancer. Science 1991; 254: 1167–73
- Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138–46
- Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991; 253: 49–53
- Ehrhart J C, Duthu A, Ullrich S, et al. Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 in a human osteosarcoma cell line. Oncogene 1988; 3: 595–603
- Lee C S, Ellison M, Charalambous D, et al. p53 oncoprotein in normal pancreas, chronic pancreatitis and pancreatic carcinoma. J Pathol 1992; 167: 151, Suppl
- Romano J W, Ehrhart J C, Duthu A, et al. Identification and characterization of a p53 gene mutation in a human osteosarcoma cell line. Oncogene 1990; 4: 1483–8